| Drug General Information |
| Drug ID |
D04CIL
|
| Former ID |
DPR000058
|
| Drug Name |
HMG-CoA reductase inhibitor
|
| Indication |
Chemotherapy or radiotherapy-induced mucositis [ICD9: 338, 528.0,780; ICD10:K12.3, R52, G89]
|
Preclinical |
[1]
|
|---|
| Company |
Mayne Pharma
|
| ChEBI ID |
ChEBI:35664
|
| Target and Pathway |
| Target(s) |
3-hydroxy-3-methylglutaryl-coenzyme A reductase |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
|
|
Superpathway of cholesterol biosynthesis
|
|
Mevalonate pathway
|
|
KEGG Pathway
|
Terpenoid backbone biosynthesis
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
AMPK signaling pathway
|
|
Bile secretion
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
TSH Signaling Pathway
|
|
PANTHER Pathway
|
Cholesterol biosynthesis
|
|
PathWhiz Pathway
|
Steroid Biosynthesis
|
|
WikiPathways
|
Statin Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Cholesterol Biosynthesis
|
| References |
| REF 1 | Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. |
|---|
